ML18212A053
| ML18212A053 | |
| Person / Time | |
|---|---|
| Site: | 03037397 |
| Issue date: | 07/31/2018 |
| From: | Frazier C F NRC/RGN-III |
| To: | Progress West Healthcare Ctr |
| References | |
| 608609 | |
| Download: ML18212A053 (4) | |
Text
NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION MATERIALS LICENSE PAGE 1 OF 4 PAGES Amendment No. 7 Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. Licensee 1. Progress West Healthcare Center 2. 2 Progress Point Parkway O'Fallon, MO 63368 6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 1 O CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 1 O CFR 35.300 D. Any byproduct material permitted by 10 CFR 31.11 7. A. Any B. Any C. Any D. Prepackaged Kits In accordance with letter dated 4. Expiration Date: July 31, 2027 May 1-------------~
- 5. Docket No.: 030-37397
\~ C. 300 millicurie~ffltal
- ~:*t D. 100 millicuries total CONDITIONS Reference No.: e 9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any diagnostic study or therapy procedure permitted by 10 CFR 35.300, limited to the oral administration of sodium iodide 1-131. D. For use in in-vitro studies.
NRC FORM 374A MATERIALS LICENSE SUPPLEMENTARY SHEET U.S. NUCLEAR REGULATORY COMMISSION License Number 24-32642-01 Amendment No. 7 Docket or Reference Number 030-37397 PAGE 2 OF 4 PAGES 10. Licensed material may be used or stored only at the licensee's facilities located at 2 Progress Point Parkway, O'Fallon, Missouri, 63368. 11. The Radiation Safety Officer (RSO) for this license is <ts>rp\~e B~JJ v11,<i-" 12. Licensed materlal shall only be used by, or LIA.the supervision of: A. Individuals permitted to work as auth"J,ed J ii.., B. The following individuals are autho~d users fo' Authorized User(M.D.,D.O.,etc.) Material Martin B. Ast., M.D. 10JIFR 3 Joelle Biernacki, M.D. Meredith Byers, M.D. Ajay Chapa, M.D. Constance Courtois, M.D. Heather V. Garrett, M.D. Punita Gupta, M.D. Lannis Elese Hall-Daniels, M.D. James Kelly, M.D. Paula M. Leiva, M.D. oral administration of sodium iodide 1-131 in .~) 3~}>0 (limitelL.to the oral administration of sodium iodide 1-131 in *ties less tharYbft.ed{t'.lal to 33 milli -. 10~35.100, 35.200 and 35.300 ~ed to the oral administration of sodium iodide 1-131 in quantifies I~ th 9 n or equql to~ millicuries) 10 CFR 3tft60,;3~2ef'!fart~5.3Cfo (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries) 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries) 10 CFR 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries) 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries) 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries)
NRC FORM 374A MATERIALS LICENSE SUPPLEMENTARY SHEET Authorized User(M.D.,D.O.,etc.)
Michael Penny, M.D. Hui Hau Shu, M.D. Robert Stachecki, M.D. Diana L. Westerfield, M.D. U.S. NUCLEAR REGULATORY COMMISSION License Number 24-32642-01 Amendment No. 7 Material and Use Docket or Reference Number 030-37397 PAGE 3 OF 4 PAGES 10CFR35.100and~.200
.. -10 CFR ~' 1J1Q\ilid
~.iG {/ 10 ClfE~ .. a~100, 35.200 and 35.3de4nited to the oral administration of sodium iodide 1-131 in ies fess than or equal to 33 mi~ietrr'~s)
FR 35.100 and 35.200 (~~lr "*,,t_ 13. The licensee will develop and will imple~fit and CFR 20.1101, that also meets require~s of the a 'ocedur~for licensed materials in accordance with 10 art 20, luf>part K, and 10 CFR 35.92. 0 NRC FORM 374A MATERIALS LICENSE SUPPLEMENTARY SHEET U.S. NUCLEAR REGULATORY COMMISSION License Number 24-32642-01 Amendment No. 7 Docket or Reference Number 030-37397 PAGE 4 OF 4 PAGES 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in ac~~cfiiE'6 ligulations.
Additionally, this license condition does not limit the licensee's ability to make changes to the radiation P(ofc;folil program as pfeli(eg,.tor in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall_g~vern unless tt!vt~ements, representations, a"M ~cedures in the licensee's application and correspondence are more restrictive than th~~ulat1ons.
- A. Application dated January 19, 2017 (Mm:1031A422)